Neurizon gets OK to test liquid form of ALS medication in Australia
WHY IT MATTERS
If the liquid formulation proves safe and effective, it could offer ALS patients an easier-to-take alternative to a tablet, which may improve medication adherence for people with swallowing difficulties—a common symptom of ALS.
A company called Neurizon Therapeutics has been approved to test a new liquid version of a drug called NUZ-001 in Australia. This drug is being developed to treat ALS, a disease that affects nerve cells and causes muscle weakness. The company is testing this liquid form in healthy volunteers, while a tablet version of the same drug is already being tested in a larger trial in the United States.
Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid formulation of NUZ-001, which the company is developing for amyotrophic lateral sclerosis (ALS), in healthy volunteers. A tablet version of NUZ-001 is being tested in a Phase 2/3 clinical trial in the U.S. The company is […] The post Neurizon gets OK to test liquid form of ALS medication in Australia appeared first on ALS News Today .